Tang Capital reports 10% stake in Aurinia Pharma
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tang Capital Management, Kevin Tang and affiliated entities amended their Schedule 13D to update their stake in Aurinia Pharmaceuticals Inc. The reporting group now beneficially owns 13,044,106 common shares, representing 10.0% of Aurinia’s outstanding common shares, based on 129,991,655 shares outstanding as of June 3, 2026.
The filing confirms Kevin Tang as Aurinia’s Chief Executive Officer and a board member, and describes multiple Tang Capital vehicles sharing voting and dispositive power over the position. The group also has potential obligations to purchase 1,000,000 additional common shares under put option contracts expiring on January 15, 2027 with a strike price of $15.00 per share, highlighting further potential exposure to Aurinia’s equity.
Insights
Tang Capital’s group reports a 10% Aurinia stake plus sizable equity-linked exposure.
The amended Schedule 13D shows Tang Capital Management, Kevin Tang, and affiliated funds collectively beneficially owning 13,044,106 Aurinia common shares, or 10.0% of shares outstanding as of June 3, 2026. Kevin Tang is also the company’s CEO and a director, concentrating influence.
The filing characterizes the holdings as for investment purposes and states the group may buy or sell securities depending on market conditions and the issuer’s prospects. It also discloses put option contracts covering 1,000,000 shares with a $15.00 strike price expiring on January 15, 2027, which could require additional share purchases, increasing exposure if exercised.
Key Figures
Key Terms
beneficially own financial
Schedule 13D regulatory
put option contracts financial
voting and dispositive power financial
joint filing agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Aurinia Pharmaceuticals Inc. (AUPH) does Tang Capital currently beneficially own?
Which entities are included as reporting persons in the Aurinia (AUPH) Schedule 13D/A amendment?
What derivative exposure to Aurinia (AUPH) does the Tang group disclose in this Schedule 13D/A?
What is the stated purpose of Tang Capital’s investment in Aurinia Pharmaceuticals (AUPH)?
AI-generated analysis. How Rhea-AI works. Not financial advice.